Pneumocystis carinii pneumonia following a second infusion of infliximab

Abstract
Sir, Anti‐tumour necrosis factor α (TNF‐α) blockade is increasingly used for severe rheumatoid arthritis (RA). There is an increased risk of infection, including atypical infection [1] associated with TNF‐α blockade. We report the development of Pneumocystis carinii pneumonia (PCP) in a man with RA shortly after commencing therapy with the anti‐TNF‐α agent infliximab (Remicade). This occurred in the setting of concomitant therapy with low‐dose weekly methotrexate and corticosteroids.

This publication has 0 references indexed in Scilit: